INFECTIOUS COMPLICATIONS IN TRANSPLANTATION: Edited by Kiran K. DhanireddyBK virus as a mediator of graft dysfunction following kidney transplantationYi, Stephanie G.a; Knight, Richard J.a; Lunsford, Keri E.a,bAuthor Information aWeill Cornell Medical College, Department of Surgery, J.C. Walter Jr. Center for Transplantation, Houston Methodist Hospital bImmunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Research Institute, Houston, Texas, USA Correspondence to Keri E. Lunsford, MD, PhD, Assistant Professor of Surgery, Weill Cornell Medical College, J.C. Walter Jr. Center for Transplantation, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Hospital and Research Institute, 6550 Fannin Street, Suite 1661, Houston, TX 77030, USA. Tel: +1 713 441 2038; fax: +1 713 790 6300; e-mail: [email protected] Current Opinion in Organ Transplantation: August 2017 - Volume 22 - Issue 4 - p 320-327 doi: 10.1097/MOT.0000000000000429 Buy Metrics Abstract Purpose of review BK virus is a significant risk factor for kidney allograft dysfunction and loss among renal transplant recipients. Currently, there is no proven effective treatment except for the reduction of immunosuppression. In this review, we discuss diagnostic challenges and current treatment options for BK in kidney transplant recipients. Recent findings Antiviral and antibiotic therapies have been employed for BK viraemia with variable efficacy. In addition, novel therapeutic regimens such as adoptive transfer of targeted T cells have been described as possible treatment options for recipients with BK nephropathy. BK can also be seen in the native kidneys of pancreas, heart, lung and liver transplant recipients, suggesting that BK screening measures should be employed to other solid organ transplant recipients. Summary Early screening for BK combined with reduction of immunosuppression remains the mainstay of treatment for BK viraemia. New therapeutic advances demonstrate promise in vitro; however, the in-vivo efficacy will be demonstrated by future studies. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.